Pharmaceutical Executive, Aug 1, 2009 - Pharmaceutical Executive

ADVERTISEMENT
Pharmaceutical Executive, Aug 1, 2009
Features
What's the Deal at Solvay?
By Walter Armstrong
The Belgian drugmaker is pursuing a sale, inking deals, issuing debt, and launching a power drug for Parkinson's—all at once.
A Hard Pill to Swallow
By George Koroneos, Online Content & News Editor
Innovative pharmaceutical companies are reaching out to physicians and consumers in an effort to get patients to take their medicine.
Betting the Pharma
By Walter Armstrong
With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on.
Columns
The Art and Science of a Global Brand
To navigate the global marketplace, pharma companies have to mobilize a multifaceted team with the training to turn raw data into meaningful insights.
With One Voice
In an era of blurred channels and information clutter, it is critical for brand managers to develop a unified strategy that bridges the gaps between audiences.
Back Page
If It Walks Like a Duck
By Peter Pitts
Dietary supplements function like drugs and are marketed like drugs. They should be regulated like ducks.
From the Editor
Sweeten the Pill
Through innovative patient compliance programs, manufacturers are taking steps to meet the needs of patients and the pharma industry.
Column
Lemonade 101
By Sander A. Flaum
Business schools must prepare students for the post-recession economy, not teach them principles applicable to 2003.
Washington Report
Coverage Vs. Control
By Jill Wechsler
Pressure to expand healthcare puts drug pricing, marketing, and innovation on the negotiating table.

ADVERTISEMENT

Click here